A method for preparing an aryl alkane compound

The synergistic effect of Pd2(dba)3, RuPhos, magnesium shavings, ZnCl2 and LiCl enabled the direct cross-coupling of aryl imidazolyl sulfonates with alkyl bromides, solving the problem of Csp2-Csp3 bond formation and providing an economical and efficient preparation method.

CN123106380APending Publication Date: 2026-11-17YANCHENG TEACHERS UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611033283.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-07-13
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies make it difficult to achieve cross-coupling reactions between aryl imidazolyl sulfonates and alkyl metal reagents via Csp2-Csp3 bonds, and the use of commercial or pre-synthesized organometallic reagents is costly and complex.

Method used

Using Pd2(dba)3 as a catalyst, RuPhos as a ligand, magnesium shavings as a metal promoter, ZnCl2 as a metal transfer reagent, and LiCl as an additive, aryl imidazolyl sulfonate was directly cross-coupled with alkyl bromide through a mild cross-coupling reaction.

Benefits of technology

This method enables the preparation of diverse biaryl compounds in high yields, avoids the use of expensive organometallic reagents, simplifies the operation steps, and is suitable for the late-stage functionalization of complex bioactive molecules, demonstrating good procedural economy and cost-effectiveness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_82
    Figure SMS_82
  • Figure SMS_84
    Figure SMS_84
  • Figure QLYQS_1
    Figure QLYQS_1
Patent Text Reader

Abstract

This invention provides a method for preparing aryl alkane compounds, specifically involving a palladium-catalyzed direct Csp reaction of aryl imidazolyl sulfonates with alkyl bromides. 2 -Csp 3 A cross-coupling reaction is used to prepare aryl alkane compounds. This method has mild reaction conditions and high yields.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of organic synthesis, specifically relating to a method for preparing aryl alkane compounds. Background Technology

[0002] Cross-coupling reactions between transition metal-catalyzed organometallic reagents and organohalides are among the most efficient strategies for constructing carbon-carbon bonds and synthesizing diverse organic molecules. In classical cross-coupling reactions, organohalides are widely used as electrophilic coupling agents. However, to further broaden the applicability of these reactions and reduce costs, the search for and development of novel electrophilic agents that can replace traditional organohalides has been an important research direction in organic synthetic chemistry.

[0003] Among the various novel electrophilic coupling reagents developed to date, aryl imidazolyl sulfonates exhibit significant advantages. These compounds can be conveniently prepared by reacting widely available phenols with 1,1'-sulfonyl diimidazole. Compared to traditional aryl p-toluenesulfonates, aryl imidazolyl sulfonates show significantly enhanced reactivity; and compared to aryl trifluoromethanesulfonates, they offer higher stability, ease of handling, and better cost-effectiveness. As highly efficient arylating agents, aryl imidazolyl sulfonates can effectively participate in various cross-coupling reactions. For example, under palladium (Pd) catalysis, aryl imidazolyl sulfonates can react with various aryl metal reagents (such as aryl magnesium, aryl zinc, aryl boron, and arylsilanes, etc.). Where Im = imidazole group, M = (Mg, B, Si, Zn).

[0004] However, to date, no method has been disclosed for aryl imidazolyl sulfonates to react with alkyl metal reagents via Csp. 2 -Csp 3 Cross-coupling, involving the formation of bonds, presents a relatively challenging challenge. Furthermore, the aforementioned cross-coupling reactions involving aryl imidazolyl sulfonates require the use of commercially available or pre-synthesized aryl metal reagents, which hinders their widespread application in organic synthesis to some extent, as most are not widely available and are relatively expensive, and some require fine manipulation under anhydrous conditions. Therefore, there remains a strong need to develop alternative methods for the direct cross-coupling of aryl imidazolyl sulfonates with organohalides, excluding the use of commercially available or pre-synthesized organometallic substances as coupling nucleophiles.

[0005] In recent years, the cross-coupling of two different electrophiles catalyzed by transition metals under reducing conditions has attracted widespread attention in the synthetic community due to its simplicity, cost-effectiveness, and ease of operation, avoiding the use of unavailable and relatively expensive organometallic reagents. In this regard, the direct cross-coupling of aryl imidazolium sulfonates with organohalides, especially those containing Csp... 3The more challenging alkyl halides with -X bonds, which may undergo β-hydride elimination when participating in cross-coupling reactions, have not yet been developed. This patent describes the efficient direct cross-coupling of aryl imidazolyl sulfonates with alkyl bromides, which proceeds smoothly with the assistance of Pd2(dba)3 as a catalyst, RuPhos as a ligand, magnesium scrap as a metal promoter, ZnCl2 as a metal transfer agent, and LiCl as an additive, yielding a variety of structurally diverse biaryl compounds in high yields. Summary of the Invention

[0006] This invention discloses a method for preparing a compound of formula III or a salt thereof, the method comprising the step of reacting a compound of formula I with a compound of formula II in the presence of a palladium catalyst, a ligand, a metal reagent, and a metal transfer agent to form a compound of formula III. , Among them, R1 is selected from C 1-6 Alkyl, halogen, -OR4, -NR5R6, 6- to 8-membered aryl, C2-C6 alkenyl, or two adjacent R1s together with the attached carbon atom to form a 6- to 8-membered aryl, 5- to 8-membered heterocyclic group. The C 1-6 Alkyl, 6- to 8-membered aryl, 5- to 8-membered heterocyclic, and C2-C6 alkenyl are each optionally surrounded by one or more elements selected from halogen, cyano, amino, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Substituted by alkoxy groups or R7 substituents; R2 is selected from imidazole groups; R3 is selected from C 1-10 Alkyl, C 3-8 Cycloalkyl, 3- to 8-membered heterocycloalkyl, wherein C 1-10 Alkyl, C 3-8 Cycloalkyl groups and 3- to 8-membered heterocycloalkyl groups are each optionally surrounded by one or more groups selected from halogen, cyano, amino, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, COOR8, C 3-8 Substituted with cycloalkyl or 6- to 8-membered aryl groups; R4 is selected from H and C. 1-6 Alkyl, 6- to 8-membered aryl, benzyl, said C 1-6 Alkyl, 6 to 8 aryl, and benzyl groups are each optionally surrounded by one or more groups selected from halogen, cyano, amino, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6Alkoxy, halogenated C 1-6 Substituents of alkoxy groups; R7 is selected from 6- to 8-membered aryl groups, wherein the 6- to 8-membered aryl group is optionally surrounded by one or more elements selected from halogens, C, and D. 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Substituents of alkoxy groups; R5, R6, and R8 are each independently selected from H and C. 1-6 alkyl; n is selected from 0, 1, 2, 3, 4, 5.

[0007] In some embodiments, the palladium catalyst is selected from PdCl2, Pd(CH3CN)2Cl2, Pd(OAc)2, Pd(acac)2, Pd(dppf)Cl2, and Pd2(dba)3; In some embodiments, the palladium catalyst is selected from Pd2(dba)3; In some embodiments, the amount of palladium catalyst used is 1% to 15% of the molar amount of the compound of formula I; In some embodiments, the amount of palladium catalyst used is 2.5%, 3%, 5%, 8%, or 10% of the molar amount of the compound of formula I.

[0008] In some implementations, the ligand is selected from... , , , , ; In some implementations, the ligand is selected from... (RuPhos).

[0009] In some embodiments, the amount of the ligand used is 1% to 10% of the molar amount of the compound of formula I; In some embodiments, the amount of the ligand used is 3%, 5%, 8%, or 10% of the molar amount of the compound of formula I; In some embodiments, the metallic reagent is selected from Mg; In some embodiments, the amount of the metal reagent used is 1-6 equivalents of the molar amount of the compound of formula I; In some embodiments, the amount of the metal reagent used is 2 or 4 equivalents of the molar amount of the compound of formula I; In some embodiments, the metal transfer agent is selected from ZnCl2; In some embodiments, the amount of the metal transfer agent is 1-5 equivalents of the molar amount of the compound of formula I; In some embodiments, the amount of the metal transfer agent is 1, 2, or 3 equivalents of the molar amount of the compound of formula I; In some embodiments, the method further comprises an additive selected from LiCl.

[0010] In some embodiments, the amount of Formula II is 1-5 equivalents of the molar amount of the compound of Formula I; In some embodiments, the amount of Formula II is 3, 4, or 2 equivalents of the molar amount of the compound of Formula I; In some embodiments, the amount of the additive is 1-5 equivalents of the molar amount of the compound of formula I; In some embodiments, the amount of the additive is 2 or 3 equivalents of the molar amount of the compound of formula I; In some embodiments, the method further comprises a solvent selected from tetrahydrofuran, 2-methyltetrahydrofuran, and methyl tert-butyl ether; In some embodiments, the method further comprises a solvent selected from tetrahydrofuran; In some embodiments, the method is carried out at 0-60°C; In some implementations, the method is carried out at 0°C, 10°C, 20°C, 25°C, 30°C, and 60°C; In some implementations, the method is carried out at 0°C; In some embodiments, the method is carried out under nitrogen protection; In some implementations, the reaction time of the method is 1-20 hours, for example 1, 3, 5, 6, 7, 8, 9, 10, 11, or 12 hours.

[0011] In some implementations, R1 is selected from C 1-6 Alkyl, halogen, -OR4, -NR5R6, 6 to 8 aryl, C2-C6 alkenyl, wherein C 1-6 Alkyl, 6- to 8-membered aryl, 5- to 8-membered heterocyclic, and C2-C6 alkenyl are each optionally surrounded by one or more elements selected from halogen, cyano, amino, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 The substituents are alkoxy groups and R7, and R4, R5, R6, and R7 are as defined above.

[0012] In some implementations, two adjacent R1 atoms together with the attached carbon atom form a 6- to 8-membered aryl group, a 5- to 8-membered heterocyclic group, or a 5- to 8-membered heterocyclic group. .

[0013] In some implementations, two adjacent R1 atoms together with the attached carbon atom form a 6-membered aryl group, a 5-membered heterocyclic group, or a 5-membered heterocyclic group. .

[0014] In some implementations, R1 is selected from C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkyl groups, halogens, -OPh, -OBn (benzyloxy), -N(Me)2, phenyl; In some embodiments, R1 is selected from C2-C6 alkenyl groups, which are optionally substituted with R7; In some embodiments, R7 is selected from 6-membered aryl groups, wherein the 6-membered aryl group is optionally surrounded by one or more elements selected from halogens, C... 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Substituents of alkoxy groups; In some embodiments, R2 is selected from imidazole groups; In some implementations, R3 is selected from C 1-10 Alkyl, C 3-8 Cycloalkyl, 3- to 8-membered heterocycloalkyl, wherein C 1-10 Alkyl, C 3-8 Cycloalkyl groups and 3- to 8-membered heterocycloalkyl groups are each optionally surrounded by one or more groups selected from halogen, cyano, C 1-6 Alkoxy, COOR8, C 3-8 Substituents of cycloalkyl and 6- to 8-membered aryl groups, R8 as defined above; In some implementations, R3 is selected from C 1-8 Alkyl, C 5-8 Cycloalkyl, 5- to 8-membered heterocycloalkyl, wherein C 1-8 Alkyl, C 5-8 Cycloalkyl groups and 5- to 8-membered heterocycloalkyl groups are each optionally surrounded by one or more groups selected from halogen, cyano, C 1-6 Alkoxy, COOR8, C 3-8 Substituents of cycloalkyl and 6- to 8-membered aryl groups, R8 as defined above; In some implementations, R4 is selected from H and C. 1-6 Alkyl, 6-membered aryl, benzyl; In some embodiments, R5, R6, and R8 are each independently selected from H, methyl, ethyl, and propyl. In some implementations, n is selected from 1.

[0015] In some embodiments, the method further includes the step of converting the compound of formula II to formula II' in the presence of Mg, LiCl, or ZnCl2: R3 is defined as described above.

[0016] In some embodiments, the method further includes the step of converting compounds of formula II' and formula I into formulas III and IV in the presence of a palladium catalyst and a ligand. , R3, R1, R2, n, palladium catalyst, and ligand are as defined above.

[0017] In some embodiments, the compound represented by Formula I is selected from: , , , , , , , , , , , , , , , , .

[0018] In some embodiments, the compound represented by Formula II is selected from: , , , , , , , , , , , , , , , .

[0019] In some embodiments, the compound represented by Formula III is selected from: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , .

[0020] The preparation method of this invention also includes one or more steps such as filtration, extraction, drying, concentration or purification (e.g., column chromatography): The method disclosed in this invention features mild reaction conditions, high yields, and a wide substrate applicability, compatible with a range of primary and secondary alkyl bromides with sensitive functional groups. This method has been successfully applied to the late-stage functionalization of complex bioactive molecules and has demonstrated excellent performance in scale-up synthesis, fully highlighting its practical value. Preliminary mechanistic studies suggest that the reaction may involve in-situ oxidative addition of magnesium to alkyl bromides, followed by transmetalation with ZnCl2 to generate an alkyl zinc intermediate, which then participates in a palladium-catalyzed cross-coupling reaction with aryl imidazolyl sulfonates. This "one-pot" strategy directly uses electrophilic aryl imidazolyl sulfonates and alkyl bromides as substrates, avoiding the use of expensive and difficult-to-obtain organometallic compounds, while also avoiding cumbersome pre-synthesis and handling of air- and moisture-sensitive organometallic reagents. This method not only demonstrates good procedural economy, cost-effectiveness, and ease of operation, but also provides a basis for the construction of Csp... 2 -Csp 3 The key provides a highly attractive alternative to traditional methods.

[0021] "Optional" or "optional" means that the event or situation subsequently described may, but does not have to, occur; the description includes the possibility or possibility that the event or situation may or may not occur. For example, "optionally halogenated or cyano-substituted C..." 1-6 "Alkyl" means that halogens or cyano groups may or may not be present. This description includes cases where alkyl groups are substituted by halogens or cyano groups and cases where alkyl groups are not substituted by halogens or cyano groups. "alkyl" refers to a saturated aliphatic hydrocarbon group, including straight-chain and branched groups with 1 to 10 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, and their various branched isomers. Alkyl groups can be substituted or unsubstituted; The term "halogenation" refers to the substitution of one or more atoms selected from fluorine, chlorine, bromine, and iodine.

[0022] "Substituted" refers to one or more hydrogen atoms in a group, preferably up to five, more preferably one to three hydrogen atoms, which are independently substituted by the corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art can determine (through experiment or theory) possible or impossible substitutions without much effort. The term "alkoxy" refers to -O-(alkyl), where alkyl is defined as described above. Non-limiting examples of alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentoxy, and cyclohexyloxy. Alkoxy groups can be substituted or unsubstituted. When substituted, the substituent can be replaced at any usable connection point, preferably one or more of the following groups, including but not limited to halogens.

[0023] The term "heterocyclic alkyl" or "heterocyclic group" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing 3 to 14 ring atoms, such as 4 or 5 ring atoms, wherein one or more ring atoms are selected from nitrogen, oxygen, or S(O). m Heteroatoms (where m is an integer from 0 to 2), excluding the ring moiety of -OO-, -OS-, or -SS-, with the remaining ring atoms being carbon. Non-limiting examples of "heterocyclic alkyl" include: , or And so on. Heterocyclic alkyl groups can be optionally substituted or unsubstituted.

[0024] The term "aryl" or "aromatic ring" refers to a 6- to 10-membered all-carbon monocyclic or fused polycyclic (i.e., a ring sharing adjacent carbon atom pairs) group with a conjugated π-electron system, such as phenyl and naphthyl.

[0025] The term "alkenyl" refers to a branched, unbranched, or cyclic carbon chain containing one or more double bonds, including but not limited to vinyl, propenyl, butenyl, isopropenyl, isobutenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, etc. Alkenyl groups can be optionally substituted or unsubstituted.

[0026] The "substituents" of this invention include, but are not limited to, halogens (such as chlorine and fluorine), cyano, nitro, amino, and C. 1-6Alkyl, C 1-6 Alkoxy, the C 1-6 Alkyl, C 1-6 The alkoxy group may be optionally replaced by one or more halogens, hydroxyl groups, cyano groups, nitro groups, amino groups, or C groups. 1-6 Alkyl or C 1-6 Alkyl-substituted.

[0027] "Hydroxy" refers to the -OH group.

[0028] “Cyano” refers to the -CN group.

[0029] "Halogen" refers to fluorine, chlorine, bromine, or iodine.

[0030] "Amino" refers to -NR a 2, R a Each independently selects hydrogen and C 1-6 Alkyl groups (such as methyl groups).

[0031] The term "filtration" in this invention is merely a description of one method of separating solids and liquids, and does not refer to only one specific operation. In actual production, methods such as centrifugation or spin-filtering also fall into this category.

[0032] The values ​​in this invention are instrument measurements and are subject to a certain degree of error. Generally speaking, ±20% is within the reasonable error range. Of course, the context in which the value is used needs to be considered, and it can be ±9%, ±8%, ±7%, ±6%, ±5%, ±4%, ±3%, ±2%, or ±1%, preferably ±5%.

[0033] The structure of the compounds was determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) are given in units of 10⁻⁶ (ppm). NMR measurements were performed using a Bruker AVANCE-400 NMR spectrometer with deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl₃), and deuterated methanol (Methanol-d4) as solvents, and tetramethylsilane (TMS) as the internal standard. Detailed Implementation

[0034] The present invention will be further described in conjunction with specific embodiments to enable those skilled in the art to better understand and implement the present invention, but the embodiments are not intended to limit the present invention.

[0035] Unless otherwise stated, all reagents (including all alkyl bromide 2) were purchased from commercial suppliers and used directly without further purification.

[0036] Aryl imidazole sulfonate I was prepared according to literature methods, and the relevant content is incorporated herein for illustrative purposes:

[0037] Diederich, F.; Stang, P. J. Metal-Catalyzed Cross-Coupling Reactions.Wiley-VCH: New York, 1998.

[0038] Netherton, M. R.; Fu, G. C. Nickel-Catalyzed Cross-Couplings ofUnactivated Alkyl Halides and Pseudohalides with Organometallic Compounds.Adv. Synth. Catal. 2004, 346, 1525-1532.

[0039] Jana, R.; Pathak, T. P.; Sigman, M. S. Advances in Transition Metal(Pd,Ni,Fe)-Catalyzed Cross-Coupling Reactions Using Alkyl-Organometallics asReaction Partners. Chem. Rev. 2011, 111, 1417-1492.

[0040] Cherney, A. H.; Kadunce, N. T.; Reisman, S. E. Enantioselective andEnantiospecific Transition-Metal-Catalyzed Cross-Coupling Reactions ofOrganometallic Reagents to Construct C-C Bonds. Chem. Rev. 2015, 115, 9587-9652.

[0041] Korch, K. M.; Watson, D. A. Cross-Coupling of HeteroatomicElectrophiles. Chem. Rev. 2019, 119, 8192–8228.

[0042] Zhao, B.; Rogge, T.; Ackermann, L.; Shi, Z. Metal-Catalysed C–Het (F,O, S, N) and C–C Bond Arylation. Chem. Soc. Rev. 2021, 50, 8903–8953.

[0043] Zhao, B.; Prabagar, B.; Shi, Z. Modern Strategies for C–HFunctionalization of Heteroarenes with Alternative Coupling Partners. Chem2021, 7, 2585–2634.

[0044] Albaneze-Walker, J.; Raju, R.; Vance, J. A.; Goodman, A. J.; Reeder,M. R.; Liao, J.; Maust, M. T.; Irish, P. A.; Espino, P.; Andrews, D. R.Imidazolylsulfonates: Electrophilic Partners in Cross-Coupling Reactions.Org. Lett. 2009, 11, 1463–1466.

[0045] Leckie, S. M.; Harkness, G. J.; Clarke, M. L. Catalytic ConstructiveDeoxygenation of Lignin-Derived Phenols: New C–C Bond Formation Processesfrom Imidazole-Sulfonates and Ether Cleavage Reactions. Chem. Commun. 2014,50, 11511–11513.

[0046] Harkness, GJ; Clarke, ML Less hindered ligands give improvedcatalysts for the nickel catalysed Grignard cross-coupling of aromaticethers. Catal. Sci. Technol. 2018, 8, 328–334.

[0047] Analytical thin-layer chromatography (TLC) was performed using a silica gel plate (0.2 mm thick); after development, it was visualized using ultraviolet light (254 nm).

[0048] Rapid column chromatography was performed using Merck silica gel (200–300 mesh) and freshly evaporated solvent.

[0049] Infrared (IR) spectra were measured using an FT-IR spectrophotometer equipped with KBr optics.

[0050] ¹H, ¹³C, and ¹F NMR spectra were determined using CDCl₃ as solvent on a Bruker Avance or Jeol 400 MHz spectrometer; tetramethylsilane (TMS) was used as the solvent for ¹H, ¹³C, and ¹F NMR spectra. 9 Internal standard for F NMR analysis.

[0051] High-resolution mass spectrometry (HRMS) was performed on a Waters Q-TOF Premier mass spectrometer (ESI source).

[0052] General Preparation Method 1: Synthesis of Arylimidazolium Sulfonate

[0053]

[0054] Add to a 100 mL round-bottom flask A 20 mL solution of THF containing 10 mmol (1 equivalent), N,N-sulfonyl diimidazole (3.9640 g, 20 mmol, 2 equivalents), and cesium carbonate (1.6291 g, 5 mmol, 0.5 equivalents) was prepared. The reaction mixture was stirred at room temperature for 12 hours, followed by quenching with 20 mL of saturated ammonium chloride solution and extraction with ethyl acetate (50 mL × 3). The combined organic phases were washed with 50 mL of brine and dried over anhydrous sodium sulfate. The extract was concentrated under reduced pressure to give a crude product, which was purified by silica gel column chromatography (using ethyl acetate / petroleum ether as eluent) to give an aryl imidazole sulfonate product, where Im = imidazole group, and R1 and n are as defined above.

[0055] General preparation method 2: Cross-coupling of aryl imidazolyl sulfonates with alkyl bromides

[0056]

[0057] Magnesium filings (48.6 mg, 2 mmol, 4 equivalents) and LiCl (42.4 mg, 1 mmol, 2 equivalents) were added to a dried Schlenk tube equipped with a magnetic stir bar. The mixture was then dried under reduced pressure for 3 minutes using a hot air gun (320 °C). After cooling to room temperature, the Schlenk tube was purged three times with nitrogen, followed by the addition of anhydrous THF (2 mL). Then, aryl imidazolium sulfonate I (0.5 mmol, 1 equivalent), Pd₂(dba)₃ (11.4 mg, 0.0125 mmol, 2.5 mol%), RuPhos (11.7 mg, 0.025 mmol, 5 mol%), and ZnCl₂ (1 mL, 1 mmol, 1 M THF solution) were added sequentially, and finally, alkyl bromide II (2 mmol, 4 equivalents) was added. The reaction mixture was stirred at 0°C for 6 hours, followed by quenching with saturated NH4Cl solution (10 mL) and extraction with ethyl acetate (20 mL × 3). The combined organic phases were washed with saturated brine (20 mL) and dried over anhydrous Na2SO4. The extract was concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (using ethyl acetate / petroleum ether as eluent) to give product III. R1, n, R2, and R3 are as defined above.

[0058] Example 1

[0059] Referring to general preparation method 2, the compounds of formula I are respectively (1a) (1b) (1c) (1d) (1e) (1f) (1g) (1h) (1i) (1j) (1k) (1l) (1m) (1n) (1o), Compound II is (2a) were prepared separately. (3aa) (3ba) (3ca) (3da, (3ea) (3fa) (3ga) (3ha) (3ia) (3ja) (3ka) (3la) (3ma) (3na) (3oa, yield 46%) c The reaction was carried out under a nitrogen atmosphere using compounds 1a-1o (0.5 mmol), 2a (2 mmol), Pd2(dba)3 (2.5 mol%), RuPhos (5 mol%), magnesium filings (2 mmol), ZnCl2 (1 mmol), and LiCl (1 mmol) in anhydrous THF (2 mL) for 6 hours at 0 °C. The above yields are the isolated yields. c. The reaction was carried out at room temperature.

[0060] Compound 3aa was purified by silica gel column chromatography with petroleum ether as the eluent. Yield: 86%, 70.8 mg. Colorless oil. 1 H NMR (400 MHz, CDCl3): δ = 7.13 (d, J = 8.7 Hz, 2H), 6.85(d, J = 8.6 Hz, 2H), 3.81 (s, 3H), 2.58 (t, J = 7.8 Hz, 2H), 1.65–1.55 (m,2H), 1.43–1.32 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H) ppm. 13 C NMR (100 MHz, CDCl3): δ = 157.5, 134.9, 129.2, 113.6, 55.2, 34.7, 33.9, 22.3, 13.9 ppm. IR(KBr): 3463, 2929, 2832, 1590, 1361, 1339, 1148, 774, 516cm -1 HRMS (m / z):calcd for C 11 H 17 O [M+H] + 165.1274, found: 165.1275.

[0061] Compound 3ba was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 60%, 65.5 mg. It is a colorless oil. 1 H NMR (400 MHz, CDCl3): δ = 7.19 (d, J = 8.6 Hz, 2H), 7.12 (d, J =7.6 Hz, 2H), 2.62 (d, J = 7.6 Hz, 2H), 1.64–1.55 (m, 2H), 1.41–1.31 (m, 2H),0.94 (t, J = 7.3 Hz, 3H) ppm. 19 F NMR (376 MHz, CDCl3): δ = -57.86 (s, 3F)ppm. 13 C NMR (100 MHz, CDCl3): δ = 147.2, 141.6, 129.6, 120.8, 120.5 (q, J =255.1 Hz), 35.0, 33.6, 22.3, 13.9 ppm. IR (KBr): 2831, 1610, 1360, 1161,1076, 950, 861, 774, 521 cm -1 HRMS (m / z): calcd for C 11 H 14 F3O [M+H] + 219.0991, found: 219.0986.

[0062] Compound 3ca was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 41%, 41.4 mg. It was a yellow oil. 1 H NMR (400 MHz, CDCl3): δ = 7.53 (d, J = 8.0 Hz, 2H), 7.29 (d, J =8.0 Hz, 2H), 2.67 (t, J = 7.8 Hz, 2H), 1.66–1.57 (m, 2H), 1.42–1.31 (m, 2H),0.94 (t, J = 7.3 Hz, 3H) ppm. 19 F NMR (376 MHz, CDCl3): δ = -62.12 (s, 3F)ppm. 13C NMR (100 MHz, CDCl3): δ = 147.0, 128.7, 127.9 (q, J = 32.3 Hz), 125.1(q, J = 3.8 Hz), 124.4 (q, J = 269.9 Hz), 35.5, 33.3, 22.3, 13.9 ppm. IR(KBr): 2928, 2832, 2716, 1609, 1362, 1159, 1078, 860, 774, 518 cm -1 HRMS (m / z): calcd for C 11 H 14 F3 [M+H] + 203.1042, found: 203.1045.

[0063] Compound 3da was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 55%, 42.2 mg. Colorless oil. 1 H NMR (400 MHz, CDCl3): δ = 7.12 (t, J = 6.3 Hz, 2H), 6.96 (t, J =8.3 Hz, 2H), 2.58 (t, J = 7.7 Hz, 2H), 1.64–1.52 (m, 2H), 1.41–1.29 (m, 2H),0.93 (t, J = 7.4 Hz, 3H) ppm. 19 F NMR (376 MHz, CDCl3): δ = -119.43 – -119.57(m, 1F) ppm. 13 C NMR (100 MHz, CDCl3): δ = 161.1 (d, J = 242.8 Hz), 138.4 (d,J = 2.9 Hz), 129.6 (d, J = 7.7 Hz), 114.9 (d, J = 20.9 Hz), 34.8, 33.8, 22.2,13.9 ppm. IR (KBr): 2928, 2832, 1598, 1388, 1362, 1157, 859, 775, 517 cm -1 .HRMS (m / z): calcd for C 10 H 14 F [M+H] + 153.1074, found: 153.1079.

[0064] Compound 3ea was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 52%, 38.8 mg. It was a yellow oil. 1 H NMR (400 MHz, CDCl3): δ = 7.16–7.07 (m, 4H), 2.60 (t, J = 8.0 Hz,2H), 2.31 (s, 3H), 1.59–1.54 (m, 2H), 1.47–1.37 (m, 2H), 0.96 (t, J = 7.3 Hz,3H) ppm. 13 C NMR (100 MHz, CDCl3): δ = 141.1, 135.8, 130.0, 128.8, 125.8,125.7, 33.0, 32.4, 22.8, 19.3, 14.0 ppm. IR (KBr): 2919, 2779, 1610, 1367,1248, 1022, 810, 724, 432 cm -1 HRMS (m / z): calcd for C 11 H 17 [M+H] + 149.1325, found: 149.1327.

[0065] Compound 3fa was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 63%, 46.8 mg. It was a colorless oil. 1 H NMR (400 MHz, CDCl3): δ = 7.18 (t, J = 7.4 Hz, 1H), 7.01 (d, J =8.9 Hz, 3H), 2.59 (t, J = 7.8 Hz, 2H), 2.35 (s, 3H), 1.67–1.55 (m, 2H), 1.43–1.33 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H) ppm. 13 C NMR (100 MHz, CDCl3): δ =142.9, 137.7, 129.2, 128.1, 126.3, 125.4, 35.6, 33.7, 22.4, 21.4, 14.0 ppm.IR (KBr): 2832, 1609, 1362, 1159, 951, 861, 775, 547cm -1 HRMS (m / z): calcdfor C11 H 17 [M+H] + 149.1325, found: 149.1329.

[0066] Compound 3ga was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 70%, 51.8 mg. Colorless oil. 1 H NMR (400 MHz, CDCl3): δ = 7.10 (s, 4H), 2.59 (t, J = 7.8 Hz, 2H), 2.34 (s, 3H), 1.65–1.56 (m, 2H), 1.43–1.32 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H)ppm. 13 C NMR (100 MHz, CDCl3): δ = 139.8, 134.9, 128.9, 128.3, 35.2, 33.8,22.4, 21.0, 14.0 cm -1 . IR (KBr): 2929, 2840, 2822, 1654, 1578, 1561, 1374,1356, 1138, 773 cm -1 HRMS (m / z): calcd for C 11 H 17 [M+H] + 149.1325, found: 149.1328.

[0067] Compound 3ha was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 55%, 52.3 mg. Colorless oil. 1 H NMR (400 MHz, CDCl3): δ = 7.33 (d, J = 8.3 Hz, 2H), 7.15 (d, J =8.4 Hz, 2H), 2.61 (t, J = 7.8 Hz, 2H), 1.67–1.58 (m, 2H), 1.45–1.36 (m, 2H),1.34 (s, 9H), 0.96 (t, J = 7.3 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ =148.3, 139.8, 128.0, 125.1, 35.1, 34.3, 33.7, 31.4, 22.5, 14.0 ppm. IR (KBr): 3482, 2959, 2928, 1735, 1511, 1241, 1020, 828, 696 cm -1 HRMS (m / z): calcd forC 14 H 23 [M+H] + 191.1794, found: 191.1787.

[0068] Compound 3ia was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 95%, 107.9 mg. It was a yellow oil. 1 H NMR (400 MHz, CDCl3): δ = 7.36–7.30 (m, 2H), 7.15 (d, J = 6.7Hz, 2H), 7.08 (t, J = 7.4 Hz, 1H), 7.01 (d, J = 8.7 Hz, 2H), 6.95 (d, J = 8.5Hz, 2H), 2.61 (t, J = 7.8 Hz, 2H), 1.66–1.57 (m, 2H), 1.43–1.33 (m, 2H), 0.95 (t, J = 7.3 Hz, 3H) ppm. 13 C NMR (100 MHz, CDCl3): δ = 157.7, 154.8, 137.9,129.6, 129.5, 122.8, 119.0, 118.4, 34.9, 33.8, 22.3, 14.0 ppm. IR (KBr): 3463, 2957, 2929, 2857, 1590, 1506, 1489, 1241, 870, 691 cm -1 HRMS (m / z):calcd for C 16 H 19 O [M+H] + 227.1430, found: 227.1432.

[0069] Compound 3ja was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 92%, 110.9 mg. It was a colorless oil. 1H NMR (400 MHz, CDCl3): δ = 7.52 (d, J = 6.6 Hz, 2H), 7.46 (t,J = 7.3 Hz, 2H), 7.40 (t, J = 7.1 Hz, 1H), 7.19 (d, J = 8.6 Hz, 2H), 6.99 (d,J = 8.6 Hz, 2H), 5.11 (s, 2H), 2.65 (t, J = 7.8 Hz, 2H), 1.71–1.62 (m, 2H), 1.49–1.39 (m, 2H), 1.02 (t, J = 7.3 Hz, 3H) ppm. 13 C NMR (100 MHz, CDCl3): δ =156.8, 137.2, 135.2, 129.2, 128.5, 127.8, 127.4, 114.5, 69.9, 34.7, 33.9,22.3, 13.9 ppm. IR (KBr): 3479, 2956, 2929, 2831, 1610, 1511, 1362, 1239,1175, 774, 514 cm -1 HRMS (m / z): calcd for C 17 H 21 O [M+H] + 241.1587, found: 241.1584.

[0070] Compound 3ka, purified by silica gel column chromatography with petroleum ether as eluent. Yield = 90%, 79.8 mg. Colorless oil. 1 H NMR (400 MHz, CDCl3): δ = 6.75–6.68 (m, 2H), 6.63 (d, J = 8.9Hz, 1H), 5.92 (s, 2H), 2.54 (t, J = 7.7 Hz, 2H), 1.61–1.52 (m, 2H), 1.40–1.30(m, 2H), 0.93 (t, J = 7.3 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ = 147.4,145.3, 136.8, 121.0, 108.8, 108.0, 100.6, 35.3, 33.9, 22.2, 13.9 ppm. IR(KBr): 3437, 2930, 2831, 1601, 1361, 1156, 859, 774, 517 cm -1 HRMS (m / z):calcd for C 11 H 15 O2 [M+H] + 179.1067, found: 179.1068.

[0071] Compound 3la was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 78%, 69.2 mg. It was a yellow oil. 1 H NMR (400 MHz, CDCl3): δ = 7.22 (t, J = 8.5 Hz, 1H), 6.65 (d, J =4.0 Hz, 3H), 2.99 (s, 6H), 2.64 (t, J = 7.8 Hz, 2H), 1.73–1.63 (m, 2H), 1.50–1.38 (m, 2H), 1.00 (t, J = 7.3 Hz, 3H) ppm. 13 C NMR (100 MHz, CDCl3): δ =150.7, 143.8, 128.8, 117.0, 112.9, 110.1, 40.7, 36.2, 33.8, 22.5, 14.0 ppm.IR (KBr): 3362, 2974, 2900, 2832, 1605, 1364, 1088, 1050, 881, 775, 518 cm -1 .HRMS (m / z): calcd for C 12 H 20 N [M+H] + 178.1590, found: 178.1594.

[0072] Compound 3ma was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 85%, 89.8 mg. It was a yellow oil. 1H NMR (400 MHz, CDCl3): δ = 7.69 (d, J = 8.0 Hz, 2H), 7.62 (d, J =8.2 Hz, 2H), 7.52 (t, J = 7.6 Hz, 2H), 7.46–7.39 (m, 1H), 7.35 (d, J = 8.2Hz, 2H), 2.75 (t, J = 7.7 Hz, 2H), 1.78–1.71 (m, 2H), 1.54–1.45 (m, 2H), 1.06 (t, J = 7.3 Hz, 3H) ppm. 13 C NMR (100 MHz, CDCl3): δ = 142.0, 141.2, 138.5,128.8, 128.7, 127.1, 127.0, 126.9, 35.3, 33.6, 22.4, 14.0 ppm. IR (KBr): 3457, 2956, 2929, 2857, 1601, 1486, 1362, 836, 761, 697 cm -1 HRMS (m / z):calcd for C 16 H 19 [M+H] + 211.1481, found: 211.1480.

[0073] Compound 3na was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 75%, 69.1 mg. It was a colorless oil. 1 H NMR (400 MHz, CDCl3): δ = 7.88–7.81 (m, 3H), 7.68 (s, 1H), 7.53–7.45 (m, 2H), 7.40 (d, J = 8.4 Hz, 1H), 2.84 (t, J = 7.8 Hz, 2H), 1.81–1.72(m, 2H), 1.52–1.42 (m, 2H), 1.03 (t, J = 7.3 Hz, 3H) ppm. 13IR (KBr): 3458, 2956, 2929, 1633, 1599,1360, 815, 774, 475 cm -1 HRMS (m / z): calcd for C 14 H 17 [M+H] + 185.1325, found: 185.1326.

[0074] Compound 3oa was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 46%, 42.8 mg. It was a colorless oil. 1 H NMR (400 MHz, CDCl3): δ = 8.07 (d, J = 8.0 Hz, 1H), 7.87 (d, J =8.3 Hz, 1H), 7.73 (d, J = 9.2 Hz, 1H), 7.56–7.46 (m, 2H), 7.44–7.39 (m, 1H), 7.34 (d, J = 8.2 Hz, 1H), 3.10 (t, J = 7.9 Hz, 2H), 1.81–1.71 (m, 2H), 1.54–1.43 (m, 2H), 1.00 (t, J = 7.4 Hz, 3H) ppm. 13 IR (KBr): 2956, 2930, 2828, 1610, 1367, 1265, 1014,774, 581 cm -1 HRMS (m / z): calcd for C 14 H 17 [M+H] + 185.1325, found: 185.1322.

[0075] Example 2

[0076] Referring to general preparation method 2, the compounds of formula I are respectively (1p) (1q), compound II is (2a) Prepared (3pa) (3qa).

[0077] Compound 3pa was purified by silica gel column chromatography using petroleum ether / ethyl acetate (petroleum ether / EtOAc = 50:1) as eluent. Yield: 59%, 91.4 mg. Yellow oil. 1 H NMR (400 MHz, CDCl3): δ = 7.23 (d,J = 7.9 Hz, 1H), 7.03–6.94 (m, 2H), 2.97–2.88 (m, 2H), 2.63–2.41 (m, 4H), 2.36–2.27 (m, 1H), 2.22–1.96 (m, 4H), 1.71–1.46 (m, 8H), 1.45–1.34 (m, 2H), 1.01–0.90 (m, 6H) ppm. 13 C NMR (100 MHz, CDCl3): δ = 220.8, 140.3, 136.8,136.1, 128.9, 125.8, 125.1, 50.4, 47.9, 44.2, 38.2, 35.8, 35.1, 33.6, 31.6,29.3, 26.5, 25.7, 22.4, 21.5, 13.9, 13.8 ppm. IR (KBr): 3459, 2929, 2856,2832, 1741, 1629, 1359, 1155, 774, 516 cm -1 HRMS (m / z): calcd for C 22 H 31 O [M+H] + 311.2369, found: 311.2373.

[0078] Compound 3qa was purified by silica gel column chromatography using petroleum ether / ethyl acetate (petroleum ether / EtOAc = 200:1) as eluent. Yield: 39%, 58.1 mg. Yellow oil. 1H NMR (400 MHz, CDCl3): δ = 7.45(d, J = 8.2 Hz, 2H), 7.20 (d, J = 8.2 Hz, 2H), 7.06 (q, J = 16.3 Hz, 2H), 6.70 (d, J = 2.3 Hz, 2H), 6.42 (t, J = 2.3 Hz, 1H), 3.85 (s, 6H), 2.64 (t, J= 7.8 Hz, 2H), 1.69–1.59 (m, 2H), 1.45–1.34 (m, 2H), 0.97 (t, J = 7.3 Hz, 3H)ppm. 13 C NMR (100 MHz, CDCl3): δ = 160.9, 142.7, 139.5, 134.5, 129.1, 128.7,127.6, 126.4, 104.4, 99.7, 55.3, 35.4, 33.5, 22.3, 13.9 ppm. IR (KBr): 3459,2929, 2856, 2832, 1741, 1629, 1359, 1155, 774, 516 cm -1 HRMS (m / z): calcd forC 20 H 25 O2 [M+H] + 297.1849, found: 297.1850.

[0079] Example 3

[0080] Referring to general preparation method 2, the compound of formula I is (1a), the compounds of formula II are respectively (2b) (2c) (2d) (2e) (2f) (2g) (2h) (2i) (2j) (2k) (2l) (2m) (2n) (2o) (2p), prepared separately (4ab) (4ac) (4ad) (4ae), (4af) (4ag) (4ah) (4ai) (4aj) (4ak) (4al) (4am) (4an) (4ao) (4ap). The reaction was carried out under a nitrogen atmosphere using 1a (0.5 mmol), 2b-p (2 mmol), Pd2(dba)3 (2.5 mol%), RuPhos (5 mol%), magnesium shavings (2 mmol), ZnCl2 (1 mmol) and LiCl (1 mmol) in anhydrous THF (2 mL) for 6 hours at 0 °C.

[0081] Compound 4ab was purified by silica gel column chromatography using petroleum ether / ethyl acetate (petroleum ether / EtOAc = 10:1) as eluent. Yield = 80%, 75.6 mg. Yellow oil. 1 H NMR (400 MHz, CDCl3): δ =7.09 (d, J = 8.6 Hz, 2H), 6.84 (d, J = 8.7 Hz, 2H), 3.79 (s, 3H), 2.60 (t, J= 7.3 Hz, 2H), 2.34 (t, J = 6.9 Hz, 2H), 1.80–1.63 (m, 4H) ppm. 13 C NMR (100MHz, CDCl3): δ = 157.9, 133.2, 129.2, 119.6, 113.8, 55.2, 34.0, 30.4, 24.7,17.0 ppm. IR (KBr): 2936, 2836, 1612, 1513, 1246, 1178, 1034, 829, 554 cm -1 .HRMS (m / z): calcd for C 12 H 16 NO [M+H] + 190.1226, found: 190.1226.

[0082] Compound 4ac was purified by silica gel column chromatography using petroleum ether / ethyl acetate (petroleum ether / EtOAc = 200:1) as eluent. Yield = 47%, 52.7 mg. Yellow oil. 1 H NMR (400 MHz, CDCl3): δ =7.10 (d, J = 8.6 Hz, 2H), 6.83 (d, J = 8.6 Hz, 2H), 4.12 (q, J = 7.2 Hz, 2H), 3.78 (s, 3H), 2.63–2.56 (m, 2H), 2.30 (t, J = 7.5 Hz, 2H), 1.97–1.87 (m, 2H), 1.25 (t, J = 7.1 Hz, 3H) ppm. 13 C NMR (100 MHz, CDCl3): δ = 173.5, 157.8,133.4, 129.3, 113.7, 60.2, 55.2, 34.2, 33.6, 26.7, 14.2 ppm. IR (KBr): 3447,2936, 1733, 1513, 1464, 1301, 1247, 1177, 1037, 812 cm -1 HRMS (m / z): calcdfor C 13 H 19 O3 [M+H] + 223.1329, found: 223.1324.

[0083] Compound 4ad was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 40%, 43.5 mg. It was a yellow oil. 1 H NMR (400 MHz, CDCl3): δ = 7.10 (d, J = 8.7 Hz, 2H), 6.85 (d, J =8.6 Hz, 2H), 3.80 (s, 3H), 2.64 (t, J = 7.5 Hz, 2H), 2.14–2.00 (m, 2H), 1.91–1.81 (m, 2H) ppm. 19 F NMR (376 MHz, CDCl3): δ = -66.04 (t, J = 15.0 Hz, 3F)ppm. 13C NMR (100 MHz, CDCl3): δ = 158.0, 132.7, 129.3, 127.2 (q, J = 274.3Hz), 113.9, 55.2, 33.7, 33.0 (q, J = 28.5 Hz), 23.7 (q, J = 3.0 Hz) ppm. IR(KBr): 2926, 2853, 1514, 1465, 1248, 1178, 1133, 1038, 830 cm -1 HRMS (m / z):calcd for C 11 H 14 F3O [M+H] + 219.0991, found: 219.0993.

[0084] Compound 4ae was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 47%, 46.1 mg. It is a colorless oil. 1 H NMR (400 MHz, CDCl3): δ = 7.10 (d, J = 8.6 Hz, 2H), 6.84 (d, J =8.6 Hz, 2H), 4.50 (t, J = 6.2 Hz, 1H), 4.38 (t, J = 6.2 Hz, 1H), 3.80 (s,3H), 2.57 (t, J = 7.7 Hz, 2H), 1.79–1.60 (m, 4H), 1.49–1.39 (m, 2H) ppm. 19 FNMR (376 MHz, CDCl3): δ = -217.89 (tt, J = 47.3, 23.7 Hz, 1F) ppm. 13 C NMR (100 MHz, CDCl3): δ = 157.7, 134.5, 129.2, 113.7, 84.1 (d, J = 164.2 Hz), 55.2, 34.8, 31.3, 30.3 (d, J = 19.3 Hz), 24.8 (d, J = 5.4 Hz) ppm. IR (KBr):3462, 2931, 2856, 1613, 1513, 1247, 1177, 1038, 829, 561 cm -1 HRMS (m / z):calcd for C 12 H 18 FO [M+H] + 197.1336, found: 197.1340.

[0085] Compound 4af was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 70%, 69.4 mg. Colorless oil. 1 H NMR (400 MHz, CDCl3): δ = 7.10 (d, J = 8.7 Hz, 2H), 6.84 (d, J =8.7 Hz, 2H), 3.79 (s, 3H), 3.55 (t, J = 6.4 Hz, 2H), 2.59 (t, J = 7.2 Hz, 2H), 1.85–1.69 (m, 4H) ppm. 13 C NMR (100 MHz, CDCl3): δ = 157.8, 133.9, 129.2,113.8, 55.2, 44.9, 34.1, 32.0, 28.8 ppm. IR (KBr): 3453, 2935, 2833, 1612,1513, 1363, 1247, 1038, 775, 518cm -1 HRMS (m / z): calcd for C 11 H 16 ClO [M+H] + 199.0884, found: 199.0885.

[0086] Compound 4ag was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 67%, 73.4 mg. It was a yellow oil. 1 H NMR (400 MHz, CDCl3): δ = 7.12 (d, J = 8.6 Hz, 2H), 6.85 (d, J =8.6 Hz, 2H), 3.81 (s, 3H), 2.57 (t, J = 7.9 Hz, 2H), 1.66–1.56 (m, 2H), 1.40–1.24 (m, 10H), 0.91 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ =157.6, 135.0, 129.2, 113.6, 55.2, 35.0, 31.9, 31.8, 29.5, 29.3 (2C), 22.7,14.1 ppm. IR (KBr): 2927, 2854, 1613, 1513, 1466, 1246, 1176, 1040, 820 cm -1 .HRMS (m / z): calcd for C 15 H 25 O [M+H] + 221.1900, found: 221.1904.

[0087] Compound 4ah was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 78%, 69.5 mg. Colorless oil. 1 H NMR (400 MHz, CDCl3): δ = 7.12 (d, J = 8.8 Hz, 2H), 6.84 (d, J =8.8 Hz, 2H), 3.80 (s, 3H), 2.60–2.55 (m, 2H), 1.66–1.55 (m, 1H), 1.54–1.46(m, 2H), 0.95 (d, J = 6.5 Hz, 6H) ppm. 13 C NMR (100 MHz, CDCl3): δ = 157.5,135.2, 129.2, 113.6, 55.2, 41.1, 32.8, 27.6, 22.5 ppm. IR (KBr): 3458, 2927,2854, 1585, 1513, 1362, 1246, 774, 516cm -1 HRMS (m / z): calcd for C 12 H 19 O [M+H] + 179.1430, found: 179.1433.

[0088] Compound 4ai was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 80%, 77.5 mg. Colorless oil. 1H NMR (400 MHz, CDCl3): δ = 7.10 (d, J = 8.5 Hz, 2H), 6.82 (d, J =8.6 Hz, 2H), 3.79 (s, 3H), 3.38 (t, J = 6.1 Hz, 2H), 3.33 (s, 3H), 2.58 (t, J= 7.2 Hz, 2H), 1.72–1.55 (m, 4H) ppm. 13 C NMR (100 MHz, CDCl3): δ = 157.6,134.5, 129.2, 113.6, 72.7, 58.5, 55.2, 34.7, 29.2, 28.2 ppm. IR (KBr): 2934,2859, 1513, 1462, 1246, 1178, 1120, 1038, 830, 513 cm -1 HRMS (m / z): calcd forC 12 H 19 O2 [M+H] + 195.1380, found: 195.1378.

[0089] Compound 4aj was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 84%, 85.5 mg. Colorless oil. 1 H NMR (400 MHz, CDCl3): δ = 7.08 (d, J = 8.5 Hz, 2H), 6.84 (d, J =8.6 Hz, 2H), 3.81 (s, 3H), 2.45 (d, J = 7.1 Hz, 2H), 1.76–1.62 (m, 5H), 1.55–1.42 (m, 1H), 1.28–1.13 (m, 3H), 1.01–0.88 (m, 2H) ppm. 13 C NMR (100 MHz, CDCl3): δ = 157.6, 133.4, 130.0, 113.4, 55.2, 43.2, 39.9, 33.1, 26.6, 26.3ppm. IR (KBr): 2923, 2851, 1612, 1512, 1244, 1177, 1039, 830, 571cm -1 HRMS(m / z): calcd for C 14 H 21O [M+H] + 205.1587, found: 205.1582.

[0090] Compound 4ak was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 57%, 56.2 mg. It was a yellow oil. 1 H NMR (400 MHz, CDCl3): δ = 7.32 (t, J = 7.3 Hz, 2H), 7.24 (d, J =7.4 Hz, 3H), 7.15 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 3.97 (s,2H), 3.81 (s, 3H) ppm. 13 C NMR (100 MHz, CDCl3): δ = 157.9, 141.5, 133.2,129.8, 128.8, 128.4, 125.9, 113.8, 55.2, 41.0 ppm. IR (KBr): 3027, 2906,2837, 1511, 1453, 1247, 1036, 770, 698, 510cm -1 HRMS (m / z): calcd for C 14 H 15 O [M+H] + 199.1117, found: 199.1118.

[0091] Compound 4al was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 73%, 76.9 mg. It was a yellow oil. 1 H NMR (400 MHz, CDCl3): δ = 7.30 (t, J = 7.2 Hz, 2H), 7.21 (t, J =8.4 Hz, 3H), 7.12 (d, J = 8.6 Hz, 2H), 6.85 (d, J = 8.6 Hz, 2H), 3.81 (s,3H), 2.90 (s, 4H) ppm. 13C NMR (100 MHz, CDCl3): δ = 157.8, 141.8, 133.9,129.3, 128.5, 128.3, 125.8, 113.7, 55.2, 38.2, 37.0 ppm. IR (KBr): 3447,2933, 2918, 2853, 1609, 1512, 1247, 1177, 1031, 821, 699, 536 cm -1 HRMS (m / z): calcd for C 15 H 17 O [M+H] + 213.1274, found: 213.1277.

[0092] Compound 4am was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 76%, 85.6 mg. 1 H NMR (400 MHz, CDCl3): δ = 7.23 (d, J = 6.9 Hz, 2H), 7.14 (d, J = 8.0 Hz, 3H), 7.06 (d, J = 8.7 Hz, 2H), 6.79 (d, J = 8.0 Hz, 2H), 3.73 (s, 3H), 2.63–2.53 (m, 4H), 1.94–1.84 (m, 2H) ppm. 13 C NMR (100 MHz, CDCl3): δ = 157.6,142.3, 134.3, 129.3, 128.4, 128.2, 125.7, 113.6, 55.1, 35.3, 34.4, 33.2 ppm.IR (KBr): 3026, 2934, 2856, 1512, 1246, 1177, 1037, 744, 699 cm -1 HRMS (m / z): calcd for C 16 H 19 O [M+H] + 227.1430, found: 227.1433. Yellow oily substance.

[0093] Compound 4an was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 62%, 54.2 mg. It is a colorless oil. 1H NMR (400 MHz, CDCl3): δ = 7.18 (d, J = 8.9 Hz, 2H), 6.85 (d, J =8.7 Hz, 2H), 3.80 (s, 3H), 3.00–2.90 (m, 1H), 2.09–2.01 (m, 2H), 1.85–1.75(m, 2H), 1.72–1.64 (m, 2H), 1.61–1.52 (m, 2H) ppm. 13 C NMR (100 MHz, CDCl3): δ= 157.6, 138.5, 127.9, 113.6, 55.2, 45.1, 34.7, 25.4 ppm. IR (KBr): 2953,2867, 1734, 1513, 1464, 1246, 1178, 1038, 827cm -1 HRMS (m / z): calcd forC 12 H 17 O [M+H] + 177.1274, found: 177.1271.

[0094] Compound 4ao was purified by silica gel column chromatography using petroleum ether as eluent. Yield: 74%, 70.0 mg. Colorless oil. 1 H NMR (400 MHz, CDCl3): δ = 7.16 (d, J = 8.6 Hz, 2H), 6.87 (d, J =8.0 Hz, 2H), 3.81 (s, 3H), 2.55–2.40 (m, 1H), 1.95–1.81 (m, 4H), 1.81–1.73(m, 1H), 1.48–1.34 (m, 4H), 1.33–1.22 (m, 1H) ppm. 13 C NMR (100 MHz, CDCl3): δ= 157.6, 140.3, 127.6, 113.6, 55.2, 43.6, 34.7, 26.9, 26.1 ppm. IR (KBr): 2919, 2848, 1514, 1449, 1285, 1252, 1177, 1032, 816, 537cm -1 HRMS (m / z):calcd for C 13 H 19 O [M+H] +191.1430, found: 191.1430.

[0095] Compound 4ap was purified by silica gel column chromatography using petroleum ether / ethyl acetate (petroleum ether / EtOAc = 100:1) as eluent. Yield: 40%, 38.1 mg. Colorless oil. 1 H NMR (400 MHz, CDCl3): δ = 7.16(d, J = 8.3 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 4.11–4.05 (m, 2H), 3.80 (s,3H), 3.57–3.48 (m, 2H), 2.77–2.65 (m, 1H), 1.85–1.71 (m, 4H) ppm. 13 C NMR (100MHz, CDCl3): δ = 158.0, 138.1, 127.5, 113.8, 68.4, 55.2, 40.6, 34.1 ppm. IR(KBr): 3463, 2934, 2837, 1610, 1514, 1247, 1130, 1038, 829, 543cm -1 HRMS(m / z): calcd for C 12 H 17 O2 [M+H] + 193.1223, found: 193.1219.

[0096] Example 4

[0097] Referring to the preparation method of compound 3aa in Example 1, the Pd2(dba)3 catalyst was replaced with the catalysts listed in Table 1.

[0098] Table 1. Selection of different catalysts a

[0099] Serial Number catalyst <![CDATA[Yield (%) b > 1 <![CDATA[CoBr2]]> 0 2 <![CDATA[CuCl2]]> 0 3 <![CDATA[CrCl2]]> 0 4 <![CDATA[FeCl3]]> 0 5 <![CDATA[NiCl2]]> 0 6 <![CDATA[PdCl2]]> <![CDATA[64 c ]]> 7 <![CDATA[Pd(CH3CN)2Cl2]]> <![CDATA[40 c ]]> 8 <![CDATA[Pd(OAc)2]]> <![CDATA[83 c ]]> 9 <![CDATA[Pd(acac)2]]> <![CDATA[65 c ]]> 10 <![CDATA[Pd(dppf)Cl2]]> <![CDATA[65 c ]]> 11 <![CDATA[Pd2(dba)3]]> <![CDATA[92 d (86) e <!-- 17 -->]]> 12 - 0 13 <![CDATA[Pd2(dba)3]]> <![CDATA[0 d,f ]]> 14 <![CDATA[Pd2(dba)3]]> <![CDATA[7 d,g ]]> 15 <![CDATA[Pd2(dba)3]]> <![CDATA[78 d,h ]]> 16 <![CDATA[Pd2(dba)3]]> <![CDATA[84 d,i ]]> 17 <![CDATA[Pd2(dba)3]]> <![CDATA[83 d,j ]]> 18 <![CDATA[Pd2(dba)3]]> <![CDATA[50 d,k ]]>

[0100] a. The reaction was carried out at 0 °C for 6 h using compound 1a (0.5 mmol), compound 2a (2 mmol), catalyst (10 mol%), RuPhos (5 mol%), magnesium scrap (2 mmol), ZnCl2 (1 mmol), and LiCl (1 mmol), with anhydrous THF (2 mL). b. Yield was determined by NMR analysis of the crude reaction mixture after post-treatment, using 1,3,5-trimethoxybenzene as an internal standard. c. 5 mol% catalyst was used. d. 2.5 mol% catalyst was used. e. Separate yields. f. RuPhos-free. g. ZnCl2-free. h. Lithium chloride-free. i. At room temperature. j. At 60 °C. k. 3 equivalents of Mg and compound 2a were used.

[0101] Example 5

[0102] Referring to the preparation method of compound 3aa in Example 1, the solvent was replaced with different solvents as shown in Table 2.

[0103] Table 2 Using different solvents a

[0104] Serial Number solvent <![CDATA[Yield (%) b > 1 THF <![CDATA[92 (86) c ]]> 2 2-MeTHF 55 3 <![CDATA[ t BuOMe]]> 26 4 1,4-dioxane 0 5 MeOH 0 6 MeCN 0 7 DMA 0 8 DMF 0 9 NMP 0 10 DMSO 0

[0105] a. 2 mL solvent was used to react compound 1a (0.5 mmol), compound 2a (2 mmol), Pd₂(dba)₃ (2.5 mol%), RuPhos (5 mol%), magnesium filings (2 mmol), ZnCl₂ (1 mmol), and LiCl (1 mmol) under a nitrogen atmosphere for 6 hours. b. Yields were determined by NMR analysis of the crude reaction mixture after post-treatment, using 1,3,5-trimethoxybenzene as an internal standard. c. Yield separation.

[0106] Example 6

[0107] Referring to the preparation method of compound 3aa in Example 1, the ligands were replaced with different ligands as shown in Table 3.

[0108] Table 3 Using different ligands a

[0109] Serial Number ligands <![CDATA[Yield (%) b > 1 L1 <![CDATA[92 (86) c ]]> 2 L2 Trace 3 L3 64 4 L4 31 5 L5 14 6 L6 0 7 L7 0 8 L8 14 9 L9 0 10 L10 0 11 L11 0 12 L12 0 13 L13 0 14 L14 0

[0110] a. Anhydrous THF (2 mL), compound 1a (0.5 mmol), compound 2a (2 mmol), Pd₂(dba)₃ (2.5 mol%), ligand (5 mol%), Mg scrap (2 mmol), ZnCl₂ (1 mmol), and LiCl (1 mmol) were reacted under a nitrogen atmosphere for 6 hours. b. Yields were determined by NMR analysis of the crude reaction mixture after post-treatment, using 1,3,5-trimethoxybenzene as an internal standard. c. Yield separation.

[0111]

[0112] Example 7

[0113]

[0114] Magnesium shavings (291.7 mg, 12 mmol, 4 equivalents) and LiCl (254.3 mg, 6 mmol, 2 equivalents) were added to a dried Schlenk tube equipped with a magnetic stir bar. The mixture was then dried under reduced pressure for 3 minutes using a hot air gun (320 °C). After cooling to room temperature, the Schlenk tube was purged with nitrogen three times, and anhydrous THF (12 mL) was added. Then, aryl imidazole sulfonate 1a (672.3 mg, 3 mmol, 1 equivalent), Pd2(dba)3 (68.7 mg, 0.075 mmol, 2.5 mol%), RuPhos (70.0 mg, 0.15 mmol, 5 mol%), ZnCl2 (6 mL, 6 mmol, 1 M THF solution), and alkyl bromide 2a (1644.2 mg, 12 mmol, 4 equivalents) were added sequentially to the tube. The reaction mixture was stirred at 0°C for 6 hours, followed by quenching with saturated NH4Cl solution (30 mL) and extraction with ethyl acetate (60 mL × 3). The combined organic phases were washed with saturated brine (60 mL) and dried over anhydrous Na2SO4. The extract was concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether) to give product 3aa in 80% yield (392.7 mg).

[0115] Example 8

[0116]

[0117] LiCl (42.4 mg, 1 mmol, 2 equivalents) was added to a dried Schlenk tube equipped with a magnetic stirrer. The LiCl was then dried under reduced pressure using a hot air gun (320 °C) for 3 minutes. After cooling to room temperature, the Schlenk tube was purged three times with nitrogen, and anhydrous THF (2 mL) was added. Next, 1a (112.1 mg, 0.5 mmol, 1 equivalent), Pd₂(dba)₃ (11.4 mg, 0.0125 mmol, 2.5 mol%), and RuPhos (11.7 mg, 0.025 mmol, 5 mol%) were added sequentially, followed by compound 5 (2 mmol, 2 mL, 1 M THF solution). The reaction mixture was stirred at 0 °C for 6 hours, then quenched with saturated NH₄Cl solution (10 mL), and extracted with ethyl acetate (EtOAc, 20 mL × 3). The organic phases were combined, washed with saturated brine (20 mL), and dried over anhydrous Na2SO4. The extract was concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (eluent: EtOAc / petroleum ether) to finally obtain product 3aa (9.2 mg, yield 11%).

[0118] Example 9

[0119]

[0120] LiCl (42.4 mg, 1 mmol, 2 equivalents) was added to a dried Schlenk tube equipped with a magnetic stir bar. The LiCl was then dried under reduced pressure using a hot air gun (320 °C) for 3 minutes. After cooling to room temperature, the Schlenk tube was purged three times with nitrogen and anhydrous THF (2 mL) was added. Next, 1a (112.1 mg, 0.5 mmol, 1 equivalent), Pd2(dba)3 (11.4 mg, 0.0125 mmol, 2.5 mol%), and RuPhos (11.7 mg, 0.025 mmol, 5 mol%) were added sequentially, followed by compound 6 [2 mmol; pre-prepared by mixing compound 5 (2 mmol, 2 mL, 1 M THF solution) with ZnCl2 (2 mmol, 2 mL, 1 M THF solution)]. The reaction mixture was stirred at 0°C for 6 hours, followed by quenching the reaction with saturated NH4Cl solution (10 mL) and extraction with ethyl acetate (20 mL × 3). The combined organic phases were washed with saturated brine (20 mL) and dried over anhydrous Na2SO4. The extract was concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether) to give product 3aa in 89% yield (73.4 mg).

Claims

1. A method for preparing an aryl alkane compound, namely, a method for preparing a compound of formula III or a salt thereof, the method comprising the step of reacting a compound of formula I with a compound of formula II in the presence of a palladium catalyst, a ligand, a metal reagent, and a metal transfer agent to form a compound of formula III. , wherein R1 is selected from C 1-6 Alkyl, halogen, -OR4, -NR5R6, 6- to 8-membered aryl, C2-C6 alkenyl, or two adjacent R1s together with the attached carbon atom to form a 6- to 8-membered aryl, 5- to 8-membered heterocyclic group. The C 1-6 Alkyl, 6- to 8-membered aryl, 5- to 8-membered heterocyclic, and C2-C6 alkenyl groups are each optionally surrounded by one or more groups selected from halogen, cyano, amino, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Substituted by alkoxy groups or R7 substituents; R2 is selected from imidazole groups; R3 is selected from C 1-10 Alkyl, C 3-8 Cycloalkyl, 3- to 8-membered heterocycloalkyl, wherein C 1-10 Alkyl, C 3-8 Cycloalkyl groups and 3- to 8-membered heterocycloalkyl groups are each optionally surrounded by one or more groups selected from halogen, cyano, amino, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, COOR8, C 3-8 Substituted with cycloalkyl or 6- to 8-membered aryl groups; R4is selected from H, C 1-6 alkyl, 6- to 8-membered aryl, benzyl, each optionally substituted with one or more substituents selected from halogen, cyano, amino, C 1-6 alkyl, 6- to 8-membered aryl, benzyl, each optionally substituted with one or more substituents selected from halogen, cyano, amino, C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkoxy, halogenated C 1-6 alkoxy, halogenated C R7is selected from 6- to 8-membered aryl optionally substituted with one or more substituents selected from halo, C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy; R5, R6, R8are each independently selected from H, C 1-6 alkyl; n is selected from 0, 1, 2, 3, 4, 5.

2. The method according to claim 1, wherein the palladium catalyst is selected from PdCl2, Pd(CH3CN)2Cl2, Pd(OAc)2, Pd(acac)2, Pd(dppf)Cl2, Pd2(dba)3; further, the amount of the palladium catalyst is 1% to 15% of the molar amount of the compound of formula I, preferably 2.5%.

3. The method according to claim 1, 2, wherein the ligand is selected from , , , , ; further, the ligand is used in an amount of 1% to 10%, preferably 5% of the molar amount of the compound of formula I.

4. The method according to any one of claims 1-3, wherein the metal reagent is selected from Mg; further, the amount of the metal reagent is 1-6 equivalents of the molar amount of the compound of formula I, preferably 4 equivalents.

5. The method according to any one of claims 1-4, wherein the metal transfer agent is selected from ZnCl2; further, the amount of the metal transfer agent is 1-5 equivalents of the molar amount of the compound of formula I, preferably 2 equivalents.

6. The method according to any one of claims 1-5, the method further comprising an additive selected from LiCl; further, the amount of the additive is 1-5 equivalents of the molar amount of the compound of formula I, preferably 2 equivalents.

7. The method according to any one of claims 1-6, wherein the method further comprises a solvent selected from tetrahydrofuran, 2-methyltetrahydrofuran, and methyl tert-butyl ether.

8. The method according to any one of claims 1-7, wherein the compound represented by formula I is selected from: 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 。 9. The method according to any one of claims 1-8, wherein the compound represented by formula II is selected from: 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 。 10. The method according to any one of claims 1-9, wherein the compound represented by formula III is selected from: 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 。